{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:47:20Z","timestamp":1785448040586,"version":"3.56.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.anai.2019.10.006","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T12:23:58Z","timestamp":1571142238000},"page":"79-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma"],"prefix":"10.1016","volume":"124","author":[{"given":"Bradley E.","family":"Chipps","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Trudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Alacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Zangrilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2019.10.006_bib1","first-page":"9868704","article-title":"Risk factors associated with irreversible airway obstruction in asthma: a systematic review and meta-analysis","volume":"2016","author":"Zhang","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.anai.2019.10.006_bib2","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1378\/chest.07-0713","article-title":"Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study","volume":"132","author":"Lee","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.anai.2019.10.006_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00108514","article-title":"Asthma, airflow limitation and mortality risk in the general population","volume":"45","author":"Huang","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2019.10.006_bib4","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jaci.2010.01.003","article-title":"Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up","volume":"125","author":"Contoli","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.10.006_bib5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1164\/ajrccm.164.5.2011026","article-title":"Factors associated with persistent airflow limitation in severe asthma","volume":"164","author":"ten Brinke","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2019.10.006_bib6","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.rmed.2008.04.011","article-title":"The course of persistent airflow limitation in subjects with and without asthma","volume":"102","author":"Guerra","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2019.10.006_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/cea.13302","article-title":"Fixed airflow obstruction relates to eosinophil activation in asthmatics","volume":"49","author":"Mogensen","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2019.10.006_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09031936.00201813","article-title":"Importance of concomitant local and systemic eosinophilia in uncontrolled asthma","volume":"44","author":"Schleich","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2019.10.006_bib9","doi-asserted-by":"crossref","first-page":"1700634","DOI":"10.1183\/13993003.00634-2017","article-title":"Severe eosinophilic asthma: a roadmap to consensus","volume":"49","author":"Buhl","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2019.10.006_bib10","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.10.006_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","article-title":"Reductions in eosinophil biomarkers by benralizumab in patients with asthma","volume":"111","author":"Pham","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2019.10.006_bib12","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.10.006_bib13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jaci.2018.01.008","article-title":"Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma","volume":"141","author":"Sehmi","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.10.006_bib14","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2019.10.006_bib15","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2019.10.006_bib16","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2019.10.006_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute\u2019s Severe Asthma Research Program","volume":"119","author":"Moore","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.10.006_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1477-7525-3-58","article-title":"Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older","volume":"3","author":"Juniper","year":"2005","journal-title":"Health Qual Life Outcomes"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619312876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619312876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:21:20Z","timestamp":1761052880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120619312876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1081120619312876"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2019.10.006","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2019.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}